Colonial Trust Advisors’s Pacific Biosciences PACB Stock Holding History

Colonial Trust Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-500	Closed	-$935	–	743
2025 Q4	$935	Hold	500	–	–	﹤0.01%	656
2025 Q3	$640	Hold	500	–	–	﹤0.01%	651
2025 Q2	$620	Hold	500	–	–	﹤0.01%	663
2025 Q1	$590	Hold	500	–	–	﹤0.01%	645
2024 Q4	$915	Hold	500	–	–	﹤0.01%	637
2024 Q3	$850	Hold	500	–	–	﹤0.01%	712
2024 Q2	$685	Buy	+500	New	+$1.01K	﹤0.01%	710

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Colonial Trust Advisors's PACB Position: Q1 2026 in Review

Colonial Trust Advisors sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 500 shares — an estimated $935 sold.

Colonial Trust Advisors first reported a position in PACB in Q2 2024 and held it in 7 quarters. The position peaked at $935 in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Colonial Trust Advisors reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
Colonial Trust Advisors sold 500 Pacific Biosciences shares in Q1 2026, an estimated $935.
Colonial Trust Advisors first reported a position in Pacific Biosciences in Q2 2024 and held it in 7 quarters.
Colonial Trust Advisors's Pacific Biosciences position peaked at $935 in Q4 2025.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Colonial Trust Advisors's 13F filing for Q1 2026, filed 12 May 2026.